|
| [February 14, 2013] |
 |
Research and Markets: Herpes Simplex Virus Treatment - Global Strategic Business Report
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/ptmq99/herpes_simplex)
has announced the addition of the "Herpes
Simplex Virus Treatment - Global Strategic Business Report"
report to their offering.
This report analyzes the worldwide markets for Herpes Simplex Virus
Treatment in US$ Million. The report provides separate comprehensive
analytics for the US, Europe, and Rest of World. Annual estimates and
forecasts are provided for the period 2009 through 2017. Also, a
six-year historic analysis is provided for these markets.
Market data and analytics are derived from primary and secondary
research. Company pofiles are primarily based upon search engine
sources in the public domain.
Key Topics Covered
I. Introduction, Methodology & Product Definitions
II. Executive Summary
1. Industry Overview
2. Treatment Of Herpes Simplex Virus Infection
3. Hsv Vaccines - An Insight
4. Herpes Simplex Virus Infection - The Disease, Causes, Symptoms, And
Diagnosis
5. Pipeline Analysis
6. Product Launches And Approvals
7. Recent Industry Activity
8. Focus On Select Global Players
9. Global Market Perspective
III. Market
1. The United States
2. Europe
3. Rest Of World
IV. Competitive Landscape
Companies Mentioned
The report profiles 38 companies including many key and niche players
such as
- Agenus
- AiCuris GmbH & Co.KG
- Astellas Pharma
- BioVex
- Clinigen Group
- Cytogenix
- Genocea Biosciences
- GlaxoSmithKline Plc
- Lumavita AG
- NanoBio Corporation
- NanoViricides
- Novartis International AG
- Sanofi
- Starpharma Holdings Limited
- Vical
For more information visit http://www.researchandmarkets.com/research/ptmq99/herpes_simplex

[ InfoTech Spotlight's Homepage ]
|